These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30707502)

  • 1. Very rare lineage switch from acute myeloid leukemia to mixed phenotype acute leukemia, B/Myeloid, during chemotherapy with no clonal evolution.
    Nomani L; Cook JR; Rogers HJ
    Int J Lab Hematol; 2019 Aug; 41(4):e86-e88. PubMed ID: 30707502
    [No Abstract]   [Full Text] [Related]  

  • 2. Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission.
    Lee SH; Abebe L; Paietta E; Einzig A; Wiernik PH
    Am J Hematol; 2009 Jul; 84(7):455-7. PubMed ID: 19507211
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Zhang X; Guo X
    Ann Hematol; 2019 Sep; 98(9):2223-2225. PubMed ID: 30980106
    [No Abstract]   [Full Text] [Related]  

  • 4. Human leukocyte antigen-DR negative de novo acute myeloid leukemia with Philadelphia chromosome.
    Inaba T; Nishimura H; Saito J; Yamane Y; Nakatani T; Yamamoto M; Uchiyama H; Fujita N
    Int J Hematol; 2008 Dec; 88(5):602-605. PubMed ID: 19034612
    [No Abstract]   [Full Text] [Related]  

  • 5. Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts--a retrospective single-center experience.
    Radujkovic A; Dietrich S; Bochtler T; Krämer A; Schöning T; Ho AD; Dreger P; Luft T
    Eur J Haematol; 2014 Aug; 93(2):112-7. PubMed ID: 24628527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients.
    Kim I; Koh Y; Yoon SS; Park S; Kim BK; Kim DY; Lee JH; Lee KH; Cheong JW; Lee HK; Kim SH; Kim H; Joo YD; Lee SM; Won JH; Park SK; Hong DS; Kim SH; Sohn SK; Kim CS; Park E; Kim MK; Park MR; Lee JH; Min YH;
    Am J Hematol; 2013 Jan; 88(1):10-5. PubMed ID: 23077109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
    Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
    Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia.
    Zhao H; Xu L; Yang Y; Shao J; Chen P; Dong X; Gu L; Li D
    Acta Haematol; 2017; 137(4):195-200. PubMed ID: 28445872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
    Maurillo L; Buccisano F; Spagnoli A; Voso MT; Fianchi L; Papayannidis C; Gaidano GL; Breccia M; Musto P; De Bellis E; Del Principe MI; Lunghi M; Lessi F; Martinelli G; Venditti A
    Ann Hematol; 2018 Oct; 97(10):1767-1774. PubMed ID: 29947973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant phenotype of plasmacytoid monocytes in acute myeloid leukemia.
    Boveri E; Castagnola C; Castello A; Magrini U
    Am J Hematol; 2008 May; 83(5):428-9. PubMed ID: 17617786
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course.
    Rizzieri D; Vey N; Thomas X; Huguet-Rigal F; Schlenk RF; Krauter J; Kindler T; Gjertsen BT; Blau IW; Jacobsen TF; Johansen M; Bergeland T; Gianella-Borradori A; Krug U
    Leuk Lymphoma; 2014 Sep; 55(9):2114-9. PubMed ID: 24255981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enterocolitis as initial presentation of acute myelogenous leukemia exacerbated by induction chemotherapy with idarubicin-cytosine arabinoside.
    Wood RA
    Mayo Clin Proc; 2002 Oct; 77(10):1133. PubMed ID: 12374257
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy.
    Lao Z; Yiu R; Wong GC; Ho A
    Asia Pac J Clin Oncol; 2015 Mar; 11(1):54-61. PubMed ID: 25545192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-partially matched cellular therapy (stem-cell microtransplantation) for acute myeloid leukaemia: description of four cases.
    Forés R; Dorado N; Vilches C; Regidor C; García-Marco JA; de Pablo R; de Laiglesia A; Lario A; Piris M; Cabrera JR
    Br J Haematol; 2014 May; 165(4):580-1. PubMed ID: 24666200
    [No Abstract]   [Full Text] [Related]  

  • 15. FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
    Candoni A; Simeone E; Tiribelli M; Malagola M; Russo D; Fanin R
    Am J Hematol; 2009 Oct; 84(10):690-2. PubMed ID: 19731308
    [No Abstract]   [Full Text] [Related]  

  • 16. How I treat older patients with acute myeloid leukemia.
    Arellano M; Carlisle JW
    Cancer; 2018 Jun; 124(12):2472-2483. PubMed ID: 29809277
    [No Abstract]   [Full Text] [Related]  

  • 17. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
    Jabbour E; Short NJ; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Kantarjian H
    Cancer; 2017 Nov; 123(22):4430-4439. PubMed ID: 28708931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemia cutis limited to the needle puncture sites.
    Kim HS; Choi MJ; Kim HO; Park YM
    J Dermatol; 2010 Apr; 37(4):393-5. PubMed ID: 20507416
    [No Abstract]   [Full Text] [Related]  

  • 19. Isolated leukemia cutis and CNS involvement in combination with cytogenetic findings of trisomy 8--two case reports.
    Kuschel B; Estey E
    Leuk Lymphoma; 1995 Dec; 20(1-2):153-5. PubMed ID: 8750637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
    Minetto P; Guolo F; Clavio M; Kunkl A; Colombo N; Carminati E; Fugazza G; Matarese S; Guardo D; Ballerini F; Di Grazia C; Raiola AM; Cagnetta A; Cea M; Miglino M; Lemoli RM; Gobbi M
    Br J Haematol; 2019 Feb; 184(3):457-460. PubMed ID: 29359798
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.